Leqvio

Inclisiran, the active ingredient in Leqvio, is a PCSK9 inhibitor (siRNA) presented as a 284 mg/1 mL solution for injection use. It treats primary hypercholesterolemia (heterozygous familial hypercholesterolemia) and mixed dyslipidemia as an adjunct to diet and statins.

GNH USA supplies Leqvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics, research institutions and procurement teams worldwide, providing reliable sourcing, regulatory support and cold‑chain logistics where required.

Leqvio is indicated for lipid‑lowering therapy in patients with elevated LDL‑cholesterol.

- Primary hypercholesterolemia (heterozygous familial hypercholesterolemia): reduces LDL‑cholesterol as an adjunct to diet and statins. - Mixed dyslipidemia: lowers LDL‑cholesterol levels when added to standard therapy.

Leqvio may be associated with adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site reactions: pain, erythema or swelling at the injection site. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Diarrhoea: occasional loose stools.

Serious or Rare Side Effects: - Severe hypersensitivity: anaphylaxis or angioedema requiring immediate medical attention. - Hepatic enzyme elevation: significant increase in ALT or AST levels. - Cardiovascular events: rare reports of myocardial infarction or stroke.

When prescribing Leqvio, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline LDL‑cholesterol: evaluate lipid profile before initiating therapy. - Monitor hepatic function: check ALT/AST periodically during treatment. - Evaluate for hypersensitivity: inquire about prior allergic reactions to injectable medicines. - Use with statins cautiously: consider potential additive effects on liver enzymes. - Pregnancy and lactation: avoid use as safety data are insufficient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leqvio can interact with other medicines, primarily affecting lipid management and hepatic safety.

Major Interactions (Avoid): - PCSK9 monoclonal antibodies: concurrent use offers no additional LDL‑cholesterol benefit and may increase injection burden. - High‑dose statins with known hepatotoxicity: combined risk of liver enzyme elevation.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): monitor INR or bleeding risk as lipid changes may affect coagulation. - Immunosuppressants: observe for altered immune response. - Vaccines: schedule administration separately to avoid confounding injection site reactions.